Document is current
Any future updates will be listed below
-
Authors
Hoff, Leonardo Santos https://orcid.org/0000-0002-2083-4796
Ravichandran, Naveen https://orcid.org/0000-0003-2014-3925
Shinjo, Samuel Katsuyuki https://orcid.org/0000-0002-3682-4517
Day, Jessica https://orcid.org/0000-0001-8528-4361
Sen, Parikshit https://orcid.org/0000-0002-1630-6026
Junior, Jucier Gonçalves https://orcid.org/0000-0001-5077-7959
Lilleker, James B. https://orcid.org/0000-0002-9230-4137
Joshi, Mrudula https://orcid.org/0000-0001-7312-351X
Agarwal, Vishwesh https://orcid.org/0000-0002-0986-8354
Kardes, Sinan https://orcid.org/0000-0002-6311-8634
Kim, Minchul https://orcid.org/0000-0001-9737-6255
Milchert, Marcin https://orcid.org/0000-0002-0943-8768
Makol, Ashima https://orcid.org/0000-0002-8748-898X
Gheita, Tamer https://orcid.org/0000-0002-1155-9729
Salim, Babur https://orcid.org/0000-0001-8430-9299
Velikova, Tsvetelina https://orcid.org/0000-0002-0593-1272
Gracia-Ramos, Abraham Edgar https://orcid.org/0000-0003-1842-2554
Parodis, Ioannis https://orcid.org/0000-0002-4875-5395
O’Callaghan, Albert Selva https://orcid.org/0000-0003-2823-9761
Nikiphorou, Elena https://orcid.org/0000-0001-6847-3726
Tan, Ai Lyn https://orcid.org/0000-0002-9158-7243
Chatterjee, Tulika https://orcid.org/0000-0001-8844-851X
Cavagna, Lorenzo https://orcid.org/0000-0003-3292-1528
Saavedra, Miguel A. https://orcid.org/0000-0003-0687-9944
Ziade, Nelly https://orcid.org/0000-0002-4479-7678
Knitza, Johannes https://orcid.org/0000-0001-9695-0657
Kuwana, Masataka https://orcid.org/0000-0001-8352-6136
Nune, Arvind https://orcid.org/0000-0002-3849-614X
Distler, Oliver https://orcid.org/0000-0002-0546-8310
Cansu, Döndü Üsküdar https://orcid.org/0000-0001-6543-3905
Traboco, Lisa https://orcid.org/0000-0002-1952-7879
Wibowo, Suryo Angorro Kusumo https://orcid.org/0000-0002-0089-0504
Tehozol, Erick Adrian Zamora https://orcid.org/0000-0002-7888-3961
Serrano, Jorge Rojas https://orcid.org/0000-0001-6980-7898
La Torre, Ignacio García-De https://orcid.org/0000-0002-9261-678X
Wincup, Chris https://orcid.org/0000-0002-8742-8311
Pauling, John D. https://orcid.org/0000-0002-2793-2364
Chinoy, Hector https://orcid.org/0000-0001-6492-1288
Agarwal, Vikas https://orcid.org/0000-0002-4508-1233
Aggarwal, Rohit https://orcid.org/0000-0001-7531-8038
Gupta, Latika https://orcid.org/0000-0003-2753-2990
,
- License Information
-
More Information
Article History
Received: 14 August 2022
Accepted: 5 October 2022
First Online: 22 October 2022
Declarations
:
: ALT has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB. CW has received travel support from Abbvie, unrelated to this manuscript. EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, Lilly and holds research grants from Pfizer and Lilly. HC has received grant support from Eli Lilly and UCB; consulting fees from Novartis, Eli Lilly, Orphazyme, Astra Zeneca; speaker for UCB, Biogen. HC is supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. JD has received research funding from CSL Limited. JBL has received speaker honoraria/participated in advisory boards for Sanofi Genzyme, Roche, and Biogen. None is related to this manuscript. JP has received consulting fees, speaking fees, and/or honoraria from Actelion, Sojournix Pharma, and Boehringer Ingelheim. None is related to this manuscript. NZ has received speaker fees, advisory board fees and research grants from Pfizer, Roche, Abbvie, Eli Lilly, NewBridge, Sanofi-Aventis, Boehringer Ingelheim, Janssen, Pierre Fabre; none is related to this manuscript. OD has/had consultancy relationship with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three years: Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur and UCB. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). RA has/had a consultancy relationship with and/or has received research funding from the following companies-Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, and Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant. Rest of the authors have no conflict of interest relevant to this manuscript.
: Ethical approval was obtained from the Institutional Ethics Committee of Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, 226014 (IEC Code: 2021-143-IP-EXP-39).
